evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,257 questions · 1,337 findings · 183 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 175 · 13.1%GRADE not reported 212 · 15.9%Very low 286 · 21.4%Low 341 · 25.5%Moderate 254 · 19%High 69 · 5.2%

Rituximab vs placebo

Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs other disease‐modifying treatments

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Rituximab vs other disease‐modifying treatments

Natalizumab · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).

2 findings from 1 review

Rituximab vs other disease‐modifying treatments

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Rituximab vs placebo

Disability worsening · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Aspirin vs vitamin K antagonist (VKA)

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review